Criteria to qualify for study: Drug used in study:
  • Confirmed MYD88 and CXCR4 mutations

LYM 165

A Phase 1b Trial of Mavorixafor, an oral CXCR4 Antagonist, in combination with Ibrutinib in patients with Waldenstrom’s Macroglobulinemia (WM) whose tumors express mutations of MYD88 and CXCR4

https://clinicaltrials.gov/ct2/show/NCT04274738

Criteria to qualify for study: Drug used in study:
  • B-Cell NHL, CLL-SLL, Waldenstrom Macroglobulinemia, Richter’s transformation, Follicular Lymphoma, MCL, MZL

HR 52

A Phase 1 Dose Escalation Study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of ARQ 531 in selected subjects with Relapsed or Refractory Hematologic Malignancies.

https://clinicaltrials.gov/ct2/show/NCT03162536